ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.7G>C (p.Glu3Gln)

dbSNP: rs2073524362
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001068360 SCV001233467 uncertain significance Li-Fraumeni syndrome 2019-03-25 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An experimental study in yeast has shown that this variant does not impair the transcriptional transactivation activity of the TP53 protein (PMID: 12826609). This variant has not been reported in the literature in individuals with TP53-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with glutamine at codon 3 of the TP53 protein (p.Glu3Gln). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and glutamine.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002282452 SCV002571868 uncertain significance not specified 2022-08-08 criteria provided, single submitter clinical testing Variant summary: TP53 c.7G>C (p.Glu3Gln) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 250540 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.7G>C in individuals affected with Li-Fraumeni Syndrome has been reported. Experimental evidence using yeast-based functional assays showed that the variant had no damaging effect on protein function (Kato_2003, PHANTM database). One ClinVar submitter has assessed the variant since 2014: the variant was classified as of uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Liquid Biopsy and Cancer Interception Group, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research RCV003128747 SCV003806394 uncertain significance Lung adenocarcinoma 2022-06-06 criteria provided, single submitter research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.